Bone Therapeutics to host Extraordinary General Meeting on 05 October 2022
REGULATED INFORMATION As a result of a technical error in the publication dated August 26, 2022, the Board of Directors...
Staff
POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. HansenINDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) --...
Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not...
Over 480 Million People Estimated to Have COPD, World’s Third Deadliest Disease, ResMed Study Reports
New prevalence figure 22–126% higher than previous estimatesPrevalence expected to reach 592 million by 2050Researchers urge global action on smoking...
Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in Funding
Leuven, BELGIUM, Boston, MA, US – September 2, 2022 – CET 10:30PM – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical...
DBV Technologies to Present at Upcoming Investor Conferences
Montrouge, France, September 2, 2022 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345...
PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery
SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality In an FDA...
Nanomix Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies
Point-of-care technology to offer patients a timely, highly accurate status of their protection against COVID-19SAN LEANDRO, Calif., Sept. 02, 2022...
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance...
Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update
HAYWARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene...
Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors
Neha Krishnamohan Neha KrishnamohanWESTLAKE VILLAGE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company...
Fate Therapeutics to Participate at Upcoming September Investor Conferences
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage...
InnovAge to Announce Fiscal Fourth Quarter 2022 Financial Results and Host Conference Call Tuesday, September 13, 2022
DENVER, Sept. 02, 2022 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV) will release its 2022 fiscal fourth quarter...
New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD,...
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
MENLO PARK, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on...
NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business
WOBURN, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Jonathan "Breck"...
Optimi Health Provides Progress Report On Year Of Commercialization
Company set to introduce psychedelic product catalogue showcasing in-house EU-GMP manufacturing expertise VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE)...
SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022
JERSEY CITY, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN),...
Opus Genetics Hosts Inaugural Patient Advocacy Outreach Webinar on Inherited Retinal Diseases
Virtual event details Opus’ unique and transparent approach to building company centered on patient need, provides update on lead programs...